As treatment advancements are made, the number of people who cannot be treated effectively is reduced. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy, discusses the exciting use of second generation inhibitors of FLT3 for acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
The use of second generation FLT3 inhibitors for AML
